Adalvo announces successful DCP Submission for Desogestrel + Ethinylestradiol (0.15mg+0.02mg) film coated tablets

We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets.

This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients.

Our Desogestrel+Ethinylestradiol 0.15mg/0.02mg film-coated tablets were developed in collaboration with one of our strategic partners, based on the reference brand Mercilon film-coated tablets. The product is a low-dose contraceptive used by women to prevent pregnancy.

According to IQVIA, Desogestrel+Ethinylestradiol (0.15mg+0.02mg) generated approximately $85mn in global sales in 2022.

Building on this accomplishment, Adalvo continues to expand their Women's Health portfolio. As a distinguished player in this domain, we are delighted to offer a wide range of products, as outlined below:

• Cyproterone + Ethinylestradiol, 2 mg + 0.035 mg
• Desogestrel, 75 mcg
• Desogestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
• Desogestrel + Ethinylestradiol, 0.15 mg + 0.03 mg
• Dienogest, 2 mg
• Drospirenone + Ethinylestradiol, 3 mg + 0.02 mg
• Drospirenone + Ethinylestradiol, 3 mg + 0.03 mg
• Levonorgestrel, 1.5 mg
• Levonorgestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
• Levonorgestrel + Ethinylestradiol, 0.15 mg + 0.03 mg
• Norethisterone, 5 mg
• Norethisterone + Estradiol, 0.5 mg + 1 mg